KDR and neoplasm: Dual inhibition of FGFR and VEGFR pathways has demonstrated synergistic suppression of lymph-angiogenesis and tumor progression in preclinical models, highlighting the therapeutic potential of targeting VEGF/VEGFR signaling in iCCA [53].